SachsForum
  SachsForum
  • EVENTS:
    • Upcoming Events >
      • 1st EBOIF Forum
      • 12th HTIF Forum
      • 25th BEF Forum
    • Recent Events >
      • 18th ELSF >
        • POST 18th ELSF
        • Participants >
          • Attendees
          • Investors
          • Presenters
          • Sponsors
          • Supporters
      • 8th NIF >
        • POST 8th NIF
        • Participants >
          • Attendees
          • Investors
          • Presenters
          • Sponsors
          • Supporters
      • 1st BOIF >
        • POST 1st BOIF
        • Participants >
          • Attendees
          • Investors
          • Presenters
          • Sponsors
          • Supporters
      • 24th BEF >
        • POST 24th BEF
        • Participants >
          • Attendees
          • Investors
          • Presenters
          • Exhibitors
          • Sponsors
          • Supporters
      • 11th HTIF >
        • POST 11th HTIF
        • Participants >
          • Attendees
          • Investors
          • Presenters
          • Supporters
      • 10th OIF >
        • POST 10th OIF
        • Participants >
          • Attendees
          • Investors
          • Presenters
          • Sponsors
          • Supporters
      • 17th ELSF >
        • POST 17th ELSF
        • Participants >
          • Attendees
          • Investors
          • Presenters
          • Exhibitors
          • Sponsors
          • Supporters
      • 5th EHTF >
        • POST 5th EHTF
        • Participants >
          • Attendees
          • Investors
          • Presenters
          • Sponsors
          • Supporters
      • 7th NIF >
        • 7th NIF Forum
        • Participants >
          • Attendees
          • Investors
          • Presenters
          • Sponsors
          • Supporters
      • 23rd BEF >
        • POST 23rd BEF
        • Participants >
          • Attendees
          • Investors
          • Presenters
          • Exhibitors
          • Sponsors
          • Supporters
      • 10th HTIF >
        • POST 10th HTIF
        • Participants >
          • Attendees
          • Investors
          • Presenters
          • Sponsors
          • Supporters
      • 9th IOIF >
        • POST 9th IOIF
        • Participants >
          • Attendees
          • Investors
          • Presenters
          • Sponsors
          • Supporters
      • 4th EHTF >
        • POST 4th EHTF
        • Participants >
          • Attendees
          • Investors
          • Presenters
          • Sponsors
          • Supporters
      • 16th ELSF >
        • POST 16th ELSF
        • Participants >
          • Attendees
          • Investors
          • Presenters
          • Sponsors
          • Supporters
      • 6th NIF >
        • POST 6th NIF
        • Participants >
          • Attendees
          • Investors
          • Showcases
          • Exhibitors
          • Sponsors
          • Supporters
      • 2nd SBISS >
        • POST 2nd SBISS
        • Participants >
          • Attendees
          • Showcases
          • Sponsors
      • 9th HTIF >
        • POST 9th HTIF
        • Participants >
          • Investors
          • Attendees
          • Presenters
          • Exhibitors
          • Sponsors
          • Supporters
      • 22nd BEF >
        • POST 22nd BEF
        • Participants >
          • Attendees
          • Investors
          • Presenters
          • Exhibitors
          • Sponsors
          • Supporters
      • 1st SBISS >
        • POST 1st SBISS
        • Participants >
          • Attendees
          • Showcases
          • Sponsors
      • 8th IOIF >
        • POST 8th IOIF
        • Participants >
          • Attendees
          • Investors
          • Showcases
          • Sponsors
          • Supporters
      • 5th NIF Forum >
        • POST 5th NIF Forum
        • Participants >
          • Attendees
          • Investors
          • Showcases
          • Sponsors
          • Supporters
      • 15th ELSF Forum >
        • POST 15th ELSF Forum
        • Participants >
          • Attendees
          • Investors
          • Showcases
          • Sponsors
          • Supporters
      • 3rd EHTF Forum >
        • POST 3rd EHTF Forum
        • Participants >
          • Attendees
          • Investors
          • Showcases
          • Sponsors
          • Supporters
      • 21st BEF Forum >
        • POST 21st BEF Forum
        • Participants >
          • Attendees
          • Investors
          • Presenters
          • Sponsors
          • Supporters
      • 8th HTIF >
        • POST 8th HTIF Forum
        • Participants >
          • Attendees
          • Investors
          • Presenters
          • Sponsors
          • Supporters
      • 7th IOIF >
        • POST 7th IOIF Forum
        • Participants >
          • Attendees
          • Investors
          • Presenters
          • Sponsors
          • Supporters
      • 14th ELSF >
        • Post 14th ELSF Forum
        • Recordings
        • Participants >
          • Attendees
          • Investors
          • Presenters
          • Sponsors
          • Supporters
      • 2nd EHTF >
        • Post 2nd EHTF Forum
        • Recordings
        • Participants >
          • Attendees
          • Investors
          • Presenters
          • Sponsors
          • Supporters
      • 4th NIF >
        • Post 4th NIF Forum
        • Participants >
          • Attendees
          • Investors
          • Presenters
          • Supporters
      • 20th BEF >
        • POST 20th BEF Forum
        • Recordings
        • Participants >
          • Presenting Companies
          • Attendees
          • Investors
          • Sponsors
          • Supporters
      • NCIF >
        • POST NCIF Forum
        • Recordings
        • Participants >
          • Presenting Companies
          • Attendees
          • Investors
          • Sponsors
          • Supporters
      • 6th IOIF >
        • POST 6th IOIF Forum
        • Participants >
          • Attendees
          • Investors
          • Presenting companies
          • Sponsors & Supporters
      • 13th ELSF >
        • POST 13th ELSF Forum
        • Participants >
          • Attendees
          • Investors
          • Presenting Companies
          • Rising Stars
          • Exhibitors
          • Sponsors
          • Supporters
      • EHTF >
        • POST EHTF Forum
        • Participants >
          • Attendees
          • Investors
          • Presenting Companies
          • Rising Stars
          • Sponsors
          • Supporters
      • 3rd NIF >
        • POST 3rd NIF Forum
        • Participants >
          • Attendees
          • Investors
          • Presenting Companies
          • Sponsors & Supporters
      • 19th BEF >
        • POST 19th BEF Forum
        • Participants >
          • Attendees
          • Investors & Analysts
          • Presenting Companies
          • Rising Stars
          • Exhibitors
          • Sponsors
          • Supporters
      • 7th HTIF >
        • POST 7th HTIF Forum
        • Participants >
          • Attendees
          • Investors & Analysts
          • Presenting Companies
          • Rising Stars
          • Exhibitors
          • Sponsors
          • Supporters
      • 5th IOBDLI >
        • POST 5th IOBDLI
        • Participants >
          • Attendees
          • Investors
          • Presenters
          • Sponsor & Supporters
      • 12th ELSCEO >
        • POST 12th ELSCEO
        • Participants >
          • Attendees
          • Presenting Companies
          • Investors
          • Sponsors
          • Supporters
          • Rising Stars
      • GFI LS >
        • POST GFI LS
        • Participants >
          • Speakers
          • Israeli Companies
          • Sponsors
          • Supporters
      • 2nd NIF >
        • POST 2nd NIF
        • Participants >
          • Attendees
          • Presenting Companies
          • Investors
          • Sponsors & Supporters
      • 18th BEF >
        • POST 18th BEF
        • Participants >
          • Attendees
          • Speakers
          • Presenting Companies
          • Exhibitors
          • Investors & Analysts
          • Sponsors
          • Supporters
          • Seeds
      • 6th MTDH >
        • POST 6th MTDH
        • Participants >
          • Attendees
          • Presenting Companies
          • Investors & Analysts
          • Sponsors
          • Supporters
          • Seeds
      • 4th IOBDLI >
        • POST 4th IOBDLI Forum
        • Participants >
          • Attendees
          • Presenting Companies
          • Investors
          • Sponsors & Supporters
      • 11th ELSCEO >
        • POST 11th ELSCEO
        • Participants >
          • Attendees
          • Investors & Advisory
          • Presenting Companies
          • Sponsors & Supporters
      • 1st NIF >
        • POST 1st NIF
        • Participants >
          • Attendees
          • Presenting Companies
          • Investors
          • Sponsors & Supporters
      • 17th BEF >
        • POST 17th BEF
        • Participants >
          • Attendees
          • Exhibitors
          • Investors
          • Presenting Companies
          • Sponsors & Supporters
      • 5th MTDH >
        • Post 5th MT&DH
        • Participants >
          • Attendees
          • Exhibitors
          • Investors
          • Presenting Companies
          • Sponsors & Supporters
      • 3rd IOBDLI >
        • 3rd Immuno-Oncology BD&L and Investment Forum >
          • Post IOBDLI Forum 2017
          • Leave Feedback
          • Participants >
            • Attendees
            • Investors & Advisory
            • Presenting Companies
            • Sponsors & Supporters
          • Agenda and Guide
      • 1st BCUSA >
        • POST BCUSA Forum
        • Participants >
          • Attendees
          • Presenting Companies
          • Investors & Analysts
          • Supporters
      • 5th CBPI >
        • 5th Annual Cancer BioPartnering & Investment Forum >
          • Post CBPI Forum 2017
          • Leave Feedback
          • Participants >
            • Attendees
            • Investors and Advisory
            • Presenting Companies
            • Sponsors & Supporters
          • Agenda & Guide
      • 2nd NBPI >
        • 2nd Annual Neuroscience BioPartnering & Investment Forum >
          • Post NBPI Forum 2017
          • Leave Feedback
          • Participants >
            • Attendees
            • Investors and Advisory
            • Presenting Companies
            • Sponsors & Supporters
          • Agenda & Guide
          • 1st Annual Neuroscience BioPartnering & Investment Forum >
            • Agenda
            • Attendees
            • One-2-One Networking
            • Presenting Companies
            • Speakers
            • Supporters
            • Venue
            • Accommodation
      • 10th ELSCEO >
        • 10th Annual European Life Sciences CEO Forum & Exhibition >
          • Post ELSCEO Forum 2017
          • Leave Feedback
          • Participants >
            • Attendees
            • Exhibitors
            • Investors & Advisory
            • Presenting Companies
          • Sponsors & Supporters
          • Venue
          • Accommodation
      • 16th BEF >
        • 16th Annual Biotech in Europe Investor Forum >
          • Post Basel Forum 2016
          • Participants >
            • Attendees
            • Exhibitors
            • Investors & Advisory
            • Presenting Companies
            • Speakers
          • Sponsors
          • Supporters
          • Accommodation
          • Venue
      • 4th MT&DH >
        • 4th Annual MedTech & Digital Health Forum >
          • Post Basel Forum 2016
          • Participants >
            • Attendees
            • Exhibitors
            • Investors & Advisory
            • Presenting Companies
            • Speakers
          • Sponsors
          • Supporters
          • Accommodation
          • Venue
      • Events Archive >
        • 2nd Immuno-Oncology BD&L and Investment Forum >
          • Agenda
          • Attendees
          • Presenting Companies
          • Sponsors
          • Supporters
          • Venue
          • Accommodation
        • 9th Annual European Life Science CEO Forum & Exhibition >
          • Agenda
          • Attending Companies
          • PresentingCompanies
          • Sponsors
          • Supporters
          • Venue
          • Accommodation
        • 4th Annual Cancer BioPartnering & Investment Forum >
          • Agenda
          • Attendees
          • One-2-One Networking
          • Presenting Companies
          • Speakers
          • Sponsors
          • Supporters
          • Venue
          • Accommodation
        • 15th Annual Biotech in Europe Forum >
          • Post Forum Site
          • Participants >
            • Attendees
            • Exhibitors
            • Financial/Advisory/Investors Attending
            • Presenting Companies
            • Speakers
            • Sponsors
            • Supporters
          • Picture Gallery
          • Webcasts
        • 3rd Annual MedTech & Digital Health Forum >
          • Post Forum Site
          • Participants >
            • Attendees
            • Financial/Advisory/Investors Attending
            • Presenting Companies
            • Speakers
            • Sponsors
            • Supporters
          • Picture Gallery
          • Webcasts
        • 1st Immuno-Oncology: BD&L and Investment Forum >
          • About the Forum
          • Picture Gallery
          • Downloadable
          • Leave a Feedback
        • 8th Annual European Life Science CEO Forum & Exhbition
        • 3rd Annual Cancer BioPartnering & Investment Forum
        • Earlier Events
  • EBOIF
    • 1st Annual European Biopharma Obesity Innovation Forum >
      • About 1st EBOIF
      • Agenda
      • Registration >
        • Regular Registration
        • Complimentary Registration
      • Attendees
      • Investors
      • Presenters
      • Exhibitors
      • Sponsors
      • Supporters
      • One-2-One Networking
      • Venue
      • Accommodation
  • HTIF
    • 12th HealthTech Investment Forum >
      • About 12th HTIF
      • Registration >
        • Regular Registration
        • Complimentary Registration
      • Attendees
      • Investors
      • Supporters
      • One-2-One Networking
      • Venue
      • Accommodation
    • Post 11th HTIF Forum
    • Post 10th HTIF Forum
    • Post 9th HTIF Forum
    • Post 8th HTIF Forum
    • Post 7th HTIF Forum
  • BEF
    • 25th Biotech in Europe Forum >
      • About 25th BEF
      • Registration >
        • Regular Registration
        • Complimentary Registration
      • Attendees
      • Investors
      • Presenters
      • Sponsors
      • Supporters
      • One-2-One Networking
      • Venue
      • Accommodation
    • Post 24th BEF Forum
    • Post 23rd BEF Forum
    • Post 22nd BEF Forum
    • Post 21st BEF Forum
    • Post 20th BEF Forum
    • Post 19th BEF Forum
  • BOIF
    • Post 1st BOIF Forum
  • NIF
    • Post 8th NIF Forum
    • Post 7th NIF Forum
    • Post 6th NIF Forum
    • Post 5th NIF Forum
    • Post 4th NIF Forum
    • Post 3rd NIF Forum
  • ELSF
    • Post 18th ELSF Forum
    • Post 17th ELSF Forum
    • Post 16th ELSF Forum
    • Post 15th ELSF Forum
    • Post 14th ELSF Forum
    • Post 13th ELSF Forum
  • ABOUT US

ABOUT | REGISTRATION | AGENDA & GUIDE | ATTENDEES
SUPPORTERS | PRESENTERS | INVESTORS
NETWORKING | â€‹VENUE | ACCOMMODATION

Picture

​ASDERA

ASDERA develops drugs for unmet needs by utilizing a patented (US Pat. 7,664,616 ) computational biostatistics platform  to identify complex genetic risk factors in small (n>500) epidemiological and phase 2/3 studies.

http://www.asdera.com/
​
Picture

Brainstorm Cell Therapeutics, Inc. - ​[NASDAQ:BCLI]

BrainStorm Cell Therapeutics (NASDAQ:BCLI) is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease and Motor Neuron Disease), Multiple Sclerosis, Parkinson’s Disease, Huntington’s Disease.
Our platform technology, NurOwn®, uses proprietary culture conditions to induce mesenchymal stem cells (MSCs) to secrete high levels of neurotrophic factors (NTFs) known to promote the survival of neurons. Our research efforts have shown that these MSC-NTF cells might be an effective tool for battling neurodegenerative diseases.

http://www.brainstorm-cell.com/

Picture

​Cantabio Pharmaceuticals, Inc.

​Cantabio Pharmaceuticals Inc. is a preclinical stage biotechnology company focusing on commercializing novel therapies and the intellectual property generated from our research and development activities for Parkinson’s disease (PD), Alzheimer’s disease (AD) and other related neurodegenerative diseases. Our strategy integrates a detailed therapeutic focus, target family biophysics, and drug discovery technology and expertise into an innovative drug discovery approach, which is currently identifying and developing small molecule pharmacological chaperones for clinical trials. In addition, the company is developing therapeutic proteins that can pass through the blood-brain barrier to supplement existing levels of proteins which display loss of function during disease conditions.

http://www.cantabio.com/
​

Picture

Embera NeuroTherapeutics, Inc.

Embera NeuroTherapeutics is a clinical stage pharmaceutical company developing novel treatments for to potentially treat a range of addictions located in the greater Boston, MA area. Embera is developing the first medication that treats addiction by moderating activity in the stress response system.

http://emberaneuro.com/

Picture

EryDel SpA

EryDel S.p.A. is a Drug Delivery Company specialized in the development of drugs and diagnostics delivered through human red blood cells via a proprietary medical device technology.

http://www.erydel.com/

Picture

Exscientia Ltd.

Our AI driven systems actively learn best practice from vast repositories of discovery data and are further enhanced with knowledge acquired from seasoned drug hunters.

With better information to hand than any researcher could acquire individually, our knowledge-driven systems design millions of novel, project-specific compounds and pre-assess each for predicted potency, selectivity, ADME and other key criteria. From this, a selection of the best, information-rich compounds are selected for synthesis and assay.

With new experimental data generated, the results are integrated and the next design cycle initiated. Rapid design-make-test cycles ensure unparalleled progress towards desired project goals.

Exscientia has already delivered exceptional productivity, generating candidates in roughly one-quarter of the time of traditional approaches.

https://www.exscientia.co.uk/
​
Picture

KemPharm, Inc. - ​[NASDAQ: KMPH]

KemPharm is a biopharmaceutical company focused on the discovery and development of new chemical entities (NCEs) to treat serious medical conditions through its proprietary and broadly applicable Ligand Activated Therapy (LAT) approach. The company utilizes its LAT technology to generate improved prodrug versions of FDA approved drugs in the high needs areas of pain, ADHD and other CNS diseases.

http://www.kempharm.com/

Picture

K-PAX Pharmaceuticals, Inc.

KPAX002, our patented compound, is an enhanced, CNS stimulant, bolstered by our proprietary mitochondrial technology, now possessing the ability to treat fatigue in patients with neurodegenerative diseases.  We have completed several clinical trials which demonstrate that KPAX002 has excellent safety and efficacy. Fatigue in neurodegenerative disorders represents a serious unmet medical need.  

​We are concurrently pursuing several indications: 1) Parkinson's disease non-motor symptoms 2) Alzheimer's disease cognitive symptoms 3) Myalgic encephalomyelitis/CFS

http://www.kpaxpharmaceuticals.com/
​
Picture

M3 Biotechnology, Inc.

M3 Biotechnology is an innovative therapeutics company that has a novel platform of disease-modifying regenerative small molecules, particularly relevant to neurodegenerative diseases. The lead compound modifies growth-factor systems, where the activation is expected to stop disease progression and even restore lost function. The company’s research has been funded by the Alzheimer’s Drug Discovery Foundation, Washington’s Life Sciences Discovery Fund, W Fund, WRF Capital, Dolby Family Ventures and other private investors.

http://m3bio.com/
​
Picture

Minoryx Therapeutics S.L.

Minoryx is a drug development company specializing in the discovery of new drugs for orphan diseases. The company targets Inborn Errors of Metabolism; a group of rare diseases of genetic origin with a high unmet medical need. The company’s leading program is a differentiated PPAR gamma agonist (MIN-102) that has multiple CNS indications. Minoryx harnesses its unique mechanism of action for potential use in X-ALD, a genetic disease characterized by progressive neurologic deterioration with no available pharmacological treatment. Minoryx is also working on a new class of compounds: non-competitive pharmacological chaperones, identified through its innovative proprietary platform – SEE-Tx. 

http://www.minoryx.com/

Picture

NeuroRx, Inc.

NeuroRx, Inc. is a clinical stage pharmaceutical company that is developing Cyclurad™, the first oral therapeutic for the treatment of suicidal crisis associated with bipolar disorder. The company is built upon 30 years of basic science and clinical expertise in understanding the role of the brain’s N-methyl-D-aspartate (NMDA) receptor in regulating human thought processes in general and in regulating depression and suicidality in specific. 

http://www.neurorxpharma.com/


Picture

Neurotrope BioScience, Inc. - ​[OTCQB:NTRP]

Neurotrope BioScience, (OTCQB:NTRP), formed in 2012, is at the forefront of the biotech industry and is focused on developing new therapies with Bryostatin 1 for the treatment of neurodegenerative diseases and developmental disorders.
Our experience, capabilities, and passion for innovative and novel drug therapies have enabled us to build a development pipeline that includes various treatment approaches with Bryostatin 1 for serious and difficult-to-treat diseases such as Alzheimer’s dementia and the Orphan diseases, Fragile X Syndrome (FXS) and Niemann-Pick Type C (NPC).

http://www.neurotropebioscience.com/Welcome_to_Neurotrope_BioScience/index.html
​

Picture

​Nexeon Medsystems, Inc.

​Nexeon Medsystems, Inc. is a global medical device company focused on providing innovative neurostimulation products that improve the quality of life of patients suffering from debilitating neurological disease.  Nexeon has developed and commercialized the Synapse™ neurostimulation system, an adaptive, closed-loop platform that can be utilized to treat a variety of neurological diseases.  

https://www.nexeonmed.com/
​

Picture

Oryzon Genomics SA - [BME:ORY]​

Oryzon is a clinical stage biopharmaceutical company and the European leader in the development of epigenetics-based therapeutics. With one compound in Phase I/IIA in oncology, ORY-1001, a highly potent LSD1 inhibitor with exquisite selectivity that has been granted orphan-drug status by the EMA, a second compound expected to enter in clinical development in 2016 for Alzheimer's Disease and additional programs in other cancer indications, the company has a broad and growing portfolio. Oryzon was founded in 2000 by Tamara Maes and Carlos Buesa. The company is headquartered in Barcelona, Spain with 30 employees, and is considered the biopharmaceutical company of reference in Spain. From its founding through 2008, the company focused its efforts in growing a genomics diagnostics business model, providing genomics services to the pharmaceutical industry in Europe. In 2008, with the acquisition of Crystax Pharmaceuticals, we started our drug discovery programs in oncology and neurodegenerative diseases, with a focus on Alzheimer’s disease and hematological cancers. Our business model is to develop our proprietary drug candidates through clinical phase II.

The company has a seasoned executive management with vast experience in the industry.

Our lead oncology program was licensed in 2014 to Roche in a collaboration transaction valued at over $500 million.

https://www.oryzon.com/

Picture

Pharmasum Therapeutics AS

Pharmasum Therapeutics is a private, Norwegian pharmaceutical company focused on the discovery and development of novel human medicines for the treatment of brain diseases, especially neurological diseases. The Company shall develop drugs to at least Proof-of-Concept stage, but will be seeking strategic partnerships with larger pharmaceutical companies potentially for early-stage collaborations, late-stage development and marketing. The preferred deal-structure takes form as a co-development partnership, where Pharmasum may reserve rights to marketing and co-promotion in certain territories. The Company shall also be open to non-organic growth through M&A processes.

http://www.pharmasum.com/

Picture

Probiodrug AG - ​[AMS:PBD] 

Probiodrug AG is a biopharmaceutical company dedicated to the research and development of new therapeutic products for the treatment of Alzheimer’s disease (“AD”). Headquartered in Halle, Germany, Probiodrug was founded in 1997 by Prof Dr Hans-Ulrich Demuth and Dr Konrad Glund and successfully developed a novel therapeutic concept for diabetes – the DP4 inhibitors / gliptins. Today Probiodrug’s aim is to become a leading company in the development of Alzheimer’s treatments and to thereby provide a better life for patients. Probiodrug has identified a new therapeutic concept linked to disease initiation and progression. The development approaches are  targeting pyroglutamate-Abeta (pGlu-Abeta) as a therapeutic strategy to fight AD.

http://www.probiodrug.de/

Picture

​ProMIS™ Neurosciences, Inc. - ​[TSE:PMN] 

Traded on the Toronto Stock Exchange (TSX), under the symbol PMN, ProMIS™ Neurosciences, Inc., is a development stage biotech company that discovers and develops game changing precision therapeutics for treatment of neurodegenerative diseases, in particular Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS).

http://promisneurosciences.com/
​
Picture

​Purdue Pharma L.P.

Purdue Pharma, a private company founded by physicians, is committed to advancing the medical care of patients with quality pharmaceutical products. We are known for our pioneering research in pain, a principal cause of human suffering. Today, we work with new partners on innovative healthcare solutions in many therapeutic areas.

http://www.purduepharma.com/

Picture

​SalubRX Therapeutics, Inc.

SalubRx Therapeutics Inc. is a privately owned semi-virtual pharmaceutical company developing new chemical entities (NCEs) for the treatment of neurological disorders. SalubRx Therapeutics Inc. has developed a platform of selective inhibitors of the nitric oxide synthase (NOS) enzyme family, the enzyme which produces nitric oxide (NO). As the first company to be able to specifically target and inhibit the individual isozymes (nNOS, eNOS, iNOS), SalubRx can avoid any of the effects of blood pressure usually associated with eNOS providing the benefits of nNOS and iNOS alone or in combination as required. NO has been implicated in a wide variety of neurological disorders from migraine through to neurodegeneration. SalubRx’s selective NOS inhibitors may be especially suited to neurodegenerative diseases as a transformative symptomatic and disease modifying treatment. Parkinson’s Disease (PD) in particular may be particularly amenable to NOS based therapeutics.

http://www.salubrx.com/
Picture

Quartet Medicine

Quartet Medicine is a private, biotechnology company focused on discovering and developing novel treatments for chronic pain and inflammation. Human genetics and preclinical target validation data point to increased tetrahydrobiopterin (BH4) as a critical mediator of peripheral nerve dysfunction and immune cell regulation. Quartet is capitalizing on these insights by safely restoring BH4 homeostasis in neuronal and inflammatory cells.
​
Quartet was founded by scientists at Boston Children’s Hospital and École Polytechnique Fédérale de Lausanne (EPFL) in Switzerland in conjunction with Atlas Venture. Quartet’s Series A investors include Atlas Venture, Novartis Venture Funds, Pfizer Venture Investments and Partners Innovation Fund. The company is based in Cambridge, Massachusetts and has research efforts underway with collaborators in the US, Europe and Asia.

https://quartetmedicine.com/

​SunRegen Healthcare AG

SunRegen Healthcare AG is a start-up company in novel neurological drug development in Basel Area in Switzerland. We have successfully discovered a key active ingredient (a compound) from Chinese medicinal herb for the treatment of neurodegenerative diseases. The compound has demonstrated potent neuroprotective, neurorescue and potential neuroregenerative effects. We aim to obtain HA approval of our product as an orphan drug as early as 2020.
Picture

​T3D Therapeutics, Inc.

A Transformational Approach to Treating Alzheimer’s Disease … and more.

T3D Therapeutics’ mission is to develop its lead drug product candidate, T3D-959, as a potential ‘First-in-Class’ and ‘Best-in-Class’ disease-modifying, breakthrough medicine for the treatment of Alzheimer’s disease, a drug with the potential to slow, stop or reverse the course of the disease.

​http://www.t3dtherapeutics.com/

Picture

vasopharm GmbH

vasopharm is a pharmaceutical company dedicated to the discovery and development of novel therapeutics for the treatment of cerebro- and cardiovascular diseases and their consequences – indications with significant unmet clinical need. The company is focused on the development of therapeutics which steer the availability of biological nitric oxide (NO) over the entire NO signal cascade and its functional counterpart the NAD(P)H oxidase (NOX) family.

http://www.vasopharm.com/
​

Sachs Associates Switzerland AG
​

​Aeschenvorstadt 4
Basel | CH-4501
​Switzerland
​

Sachs Associates Ltd.

New Derwent House
69-73 Theobalds Road
​London | WC1X 8TA
United Kingdom
​

T: +44 203 463 4890
E: [email protected]

© COPYRIGHT 2023. ALL RIGHTS RESERVED.